DRUG
Fiasp
Fiasp Insulin delivered in a basal-bolus manner.
Status
Completed
Phase
Not applicable
Enrollment
36
Locations
1
Results
Not posted
Publications
1
Study summary
One of the main challenges in maintaining tight glucose control in a closed-loop system occurs at meal times. Amylin is a gluco-regulatory beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli, and is deficient in patients with type 1 diabetes. Amylin, in the postprandial period, contributes to regulating glucose levels by delaying gastric emptying, suppressing nutrient-stimulated glucagon secretion, and increasing satiety. Pramlintide is a synthetic analog of the hormone amylin. A closed-loop system that delivers both insulin and pramlintide, based on glucose sensor readings, has the potential to better normalize glucose levels, especially during the post-prandial period. The aim of this project is to assess whether co-administration of pramlintide with the improved insulin aspart formulation - Fiasp, in an artificial pancreas system, will alleviate the need for carb counting by replacing it with a simple meal announcement, without degrading the quality of glycemic control in a closed-loop therapy.
Interventions
DRUG
Fiasp Insulin delivered in a basal-bolus manner.
DRUG
Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
DRUG
Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
DEVICE
Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
Timeline
First posted
Nov 15, 2019
Study start
Feb 14, 2020
Primary completion
Jan 30, 2022
Study completion
Jan 30, 2022
Results posted
Not reported
Registry updated
Oct 10, 2022
Outcomes
Each participant's time in target range
Time frame · 12 days
Time in target range (3.9-10mmol/L)
Mean score of the Emotional Burden section of the Diabetes Distress Scale
Time frame · 12 days
Average of all question's scores (from 1-6). Higher score means more emotional burden.
Each participant's percentage of time of glucose levels spent between 3.9 and 7.8 mmol/L
Time frame · 12 days
Each participant's percentage of time of glucose levels spent between 3.9 and 10 mmol/L
Time frame · 12 days
Each participant's percentage of time of glucose levels spent below 3.9, 3.3, and 2.8 mmol/L
Time frame · 12 days
Each participant's percentage of time of glucose levels spent above 7.8, 10, 13.9 and 16.7 mmol/L
Time frame · 12 days
Each participant's mean glucose level
Time frame · 12 days
Each participant's standard deviation of glucose levels as a measure of glucose variability
Time frame · 12 days
Each participant's number of hypoglycemia events defined as at least 15 min below 3.0 mmol/L
Time frame · 12 days
Each participant's number of Gastrointestinal symptoms
Time frame · 12 days
Each participant's total insulin delivery
Time frame · 12 days
Eligibility
Inclusion Criteria: 1. Signed and dated written informed consent 2. Males and females ≥ 12 years of age 3. HbA1c ≤ 12% 4. Insulin pump use for at least 3 months 5. Clinical diagnosis with type 1 diabetes for at least 12 months. The diagnosis of T1D is based on the investigator's clinical judgment; C peptide level and antibody determinations are not planned. 6. Women of child-bearing potential must be ready and able to use a highly effective method of birth control. Women of childbearing potential are females who have experienced \[the first occurrence of menstruation\] and do not meet the criteria for women not of childbearing potential. Women not of childbearing potential are females who are permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Exclusion Criteria: Participants who meet any of the following criteria are not eligible for the study: 1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2 inhibitors, GLP-1 agonists, Metformin, Acarbose, etc.…). 2. Current use of glucocorticoid medication. 3. Use of medication that alters gastrointestinal motility. 4. Planned or ongoing pregnancy. 5. Breastfeeding individuals. 6. Severe hypoglycemic episode within one month of admission. 7. Severe diabetes ketoacidosis episode within one month of admission. 8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. 9. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 10. Known hypersensitivity to any of the study drugs or their excipients. 11. Individuals with confirmed gastroparesis. 12. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. 13. Unable to travel to research center within 3h if needed during study interventions 14. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.). Study Discontinuation/Withdrawal 1. Failure to comply with the protocol. 2. Pregnancy. 3. After an event which the PI believes it is not in the best interest for the patient to continue the trial.
Study locations
Canada. Showing up to 24 locations stored in the fast local snapshot.
3555 University Street
Montreal, Quebec, Canada
Related trials
University of Copenhagen · Healthy Adult Participants · Bone Physiology
Not applicable
Not yet recruiting
15
2026-07
Oregon Health and Science University · Type 1 Diabetes
Not applicable
Completed
33
2026-06
Boston University · Alzheimer Disease · Mild Cognitive Impairment
Early Phase 1
Active, not recruiting
57
2026-05
Esbjerg Hospital - University Hospital of Southern Denmark · Obesity · Appetite Regulation
Phase 2 / Phase 3
Withdrawn
0
2026-04
University Hospital, Gentofte, Copenhagen · Obesity & Overweight
Not applicable
Recruiting
18
2026-04
Danish Headache Center · Headache Disorders, Secondary · Brain Diseases
Not applicable
Not yet recruiting
21
2026-01
Danish Headache Center · Headache Disorders, Primary · Headache Disorders
Not applicable
Not yet recruiting
21
2026-01
McGill University Health Centre/Research Institute of the McGill University Health Centre · type1diabetes · Diabetes Mellitus, Type 1
Phase 2 / Phase 3
Unknown
30
2024-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.